All News

Mirati Therapeutics Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares

Ref: PR Newswire

Tags: Press Release Mirati Therapeutics Corporate Affairs

Ocumension Therapeutics Strengthens Pipeline for Posterior Segment Eye Diseases

Ref: PR Newswire

Tags: Press Release Ocumension Therapeutics Luye Pharma Corporate Affairs Licensing Eylea LY09004

3DBio Therapeutics, Inc. Strengthens Board of Directors, Welcomes Scott Dylla

Ref: PR Newswire

Tags: People News AbbVie 3DBio Therapeutics Corporate Affairs

China's Clover applies for Philippines COVID-19 vaccine trial

Ref: MSN

Tags: NewsPoints Clover Biopharmaceuticals COVID-19 Immunisation Food and Drug Administration (Philippines)Regulatory Affairs

The General Court of the European Union agrees with PharmaMar on the ruling on Aplidin (plitidepsin)

Ref: PharmaMar

Tags: Press Release Zeltia European Union Myeloma European Commission EMA Corporate Affairs Aplidin

RDIF and União Química file documents for registration of Sputnik V vaccine with regulator in Brazil

Ref: RDIF

Tags: Press Release Immunisation COVID-19 Anvisa Regulatory Affairs Sputnik V

Women's cancer biotech Olema Pharmaceuticals files for a $100 million IPO

Ref: NASDAQ

Tags: NewsPoints Olema Oncology Corporate Affairs

Use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) beyond 20 weeks of pregnancy and risk of kidney damage in unborn babies, leading to low amniotic fluid

Ref: CNW

Tags: Press Release Canada Pregnancy FDA Health Canada Regulatory Affairs aspirin celecoxib diclofenac ibuprofen naproxen

The Results of the Phase 3 Study of Henlius’ Adalimumab Biosimilar HLX03 Presented on EADV 2020

Ref: Henlius

Tags: Press Release Henlius Biotech Psoriasis Clinical Research (R&D) Medical Affairs EADV adalimumab HLX03

European Investment Bank provides Minoryx with up to €25 million to support development of breakthrough therapies in orphan neurodegenerative diseases

Ref: Minoryx Therapeutics

Tags: Press Release Minoryx Therapeutics Corporate Affairs leriglitazone